---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-228322"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:34:55.370337+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience wins arbitration; panel finds no breach, no damages to EOC

## Summary
- Arbitration panel issued Final Award on Sept 26, 2024, in favor of Aadi Bioscience.
- Panel concluded Aadi did not breach the December 2020 EOC License Agreement.
- EOC Pharma sought monetary damages; none awarded.
- Dispute began in June 2022, centered on alleged failure to provide manufacturing info.
- Outcome removes a significant legal overhang for the company.

## SEC filing metadata
- accession: 0001193125-24-228322
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312524228322/0001193125-24-228322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312524228322/d871823d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-228322
- JSON: https://secwatch.observer/filing/0001193125-24-228322.json
- Plain text: https://secwatch.observer/filing/0001193125-24-228322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.